Primary, Fully Characterized autologous AML System allows the correlation of T Cell Activation with Leukemia Cell survival upon IO treatment in a novel autologous system 

One of the main obstacles in developing effective immunotherapies for AML is the lack of relevant translational models that accurately represent immune cells in the disease. The intrinsic heterogeneity of AML further complicates the translation of research into successful therapies. Additionally, the bone marrow microenvironment in AML patients induces immunosuppression, allowing immune escape and hindering immune surveillance. Therefore, using well-characterized pre-clinical models derived from primary patient samples that include autologous immune cells and replicate the  microenvironment is essential.

• Our primary AML models cultured using the proprietary autologous platform retain viable and functional immune cells alongside leukemic cells throughout the assay.

• A correlation was observed between cytotoxic and helper T-cell activation and T-cell-dependent cancer cell killing upon immune stimulation.

• Recognizing that different AML subtypes may respond differently to treatments, we provide classified, deeply characterized primary autologous AML models for effective drug testing in relevant model systems.

• This dataset demonstrates that the model is an ideal system for testing immune-oncology (IO) drugs in an autologous AML ex-vivo context, with potential to improve future treatments.